LIGAND PHARMA
LIGAND PHARMA operates in Diversified Metals & Mining.
LIGAND PHARMA - Asset Resilience Ratio
LIGAND PHARMA (LGDN) has an Asset Resilience Ratio of 16.34% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2023)
This chart shows how LIGAND PHARMA's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down LIGAND PHARMA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €156.02 Million | 16.34% |
| Total Liquid Assets | €156.02 Million | 16.34% |
Asset Resilience Insights
- Good Liquidity Position: LIGAND PHARMA maintains a healthy 16.34% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
LIGAND PHARMA Industry Peers by Asset Resilience Ratio
Compare LIGAND PHARMA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MANHATTAN ASSOC
BE:MHT |
Other | 0.00% |
|
TV BROADCAST
MU:TBCN |
Other | 2.06% |
|
FIRST CITIZENS BC A
BE:FC6A |
Other | 12.78% |
|
COSTCO WHSL
MU:CTO |
Other | 1.77% |
|
GOLDMAN SACHS GROUP - Dusseldorf Stock Exchang
DU:GOS |
Other | 1.39% |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO |
Other | 0.43% |
Annual Asset Resilience Ratio for LIGAND PHARMA (2016–2023)
The table below shows the annual Asset Resilience Ratio data for LIGAND PHARMA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 18.72% | €147.35 Million | €787.22 Million | -3.16pp |
| 2022-12-31 | 21.88% | €166.86 Million | €762.67 Million | -2.90pp |
| 2021-12-31 | 24.78% | €321.59 Million | €1.30 Billion | -1.90pp |
| 2020-12-31 | 26.69% | €363.57 Million | €1.36 Billion | -40.09pp |
| 2019-12-31 | 66.78% | €998.32 Million | €1.49 Billion | +15.43pp |
| 2018-12-31 | 51.35% | €647.41 Million | €1.26 Billion | +24.37pp |
| 2017-12-31 | 26.98% | €181.04 Million | €671.02 Million | +6.65pp |
| 2016-12-31 | 20.33% | €122.30 Million | €601.59 Million | -- |